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Background: Malignant glioma is the most devastating and aggressive tumour in the brain and is characterised by
high morbidity, high mortality and extremely poor prognosis. The main purpose of the present study was to
investigate the effects of schisandrin B (Sch B) on glioma cells both in vitro and in vivo and to explore the possible
anticancer mechanism underlying Sch B-induced apoptosis and cell cycle arrest.
Methods: The anti-proliferative ability of Sch B on glioma cells were assessed by MTT and clony formation assays.
Flow cytometric analysis was used to detect cell cycle changes. Apoptosis was determined by Hoechst 33342
staining and annexin V/PI double-staining assays. The mitochondrial membrane potential was detected by
Rhodamine 123 staining. The in vivo efficacy of Sch B was measured using a U87 xenograft model in nude mice.
The expressions of the apoptosis-related and cell cycle-related proteins were analysed by western blot. Student’s
t-test was used to compare differences between treated groups and their controls.
Results: We found that Sch B inhibited growth in a dose- and time-dependent manner as assessed by MTT assay.
In U87 and U251 cells, the number of clones was strongly suppressed by Sch B. Flow cytometric analysis revealed
that Sch B induced cell cycle arrest in glioma cells at the G0/G1 phase. In addition, Sch B induced glioma cell apoptosis
and reduced mitochondrial membrane potential (ΔΨm) in a dose-dependent manner. Mechanically, western blot
analysis indicated that Sch B induced apoptosis by caspase-3, caspase-9, PARP, and Bcl-2 activation. Moreover, Sch
B significantly inhibited tumour growth in vivo following the subcutaneous inoculation of U87 cells in athymic
nude mice.
Coclusions: In summary, Sch B can reduce cell proliferation and induce apoptosis in glioma cells and has potential
as a novel anti-tumour therapy to treat gliomas.
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Glioma, which is characterised by rapid proliferation and
diffuse invasion, is one of the most common malignant
brain tumours in adults. In the United States, malignant
gliomas account for approximately 70% of malignant
primary brain tumours in adults [1]. Because surgical
treatment is unable to remove all malignant glioma
cells, it is difficult to eliminate this type of malignancy.
As a result, malignant gliomas are associated with high
morbidity, high mortality and extremely poor prognosis* Correspondence: zhwm61@126.com; zhipeng.su@gmail.com
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unless otherwise stated.[2-7]. Tumour recurrence usually recurs within 6.9
months, resulting in a median patient survival of just
12–15 months following diagnosis [1]. Moreover, high
drug resistance and the blood–brain barrier usually
lower the efficacy of chemotherapy drugs [8]. Hence,
new effective treatments and drugs are urgently needed to
improve outcomes for patients with malignant gliomas.
Schisandrin B (Sch B, Figure 1), extracted from the fruit
of Schisandra chinensis Baill, has been used in traditional
Chinese medicine to treat hepatitis and myocardial disor-
ders [9]. In addition, Sch B has been reported to possess
antitumor activity in various human cancers, including
breast cancer, gastric cancer and hepatoma [10-12]. Pre-
vious studies have shown that Sch B can enhance theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The chemical structure of Sch B.
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cells but not normal cells via caspase-9 activation [13].
Sch B attenuates cancer invasion and metastasis [14]
and inhibits ATR protein kinase activity when DNA
damage occurs [15]. However, to the best of our know-
ledge, the effects of Sch B on glioma cells and the
underlying mechanisms of these effects have not been
previously reported. In this study, we investigated the
effects of Sch B on the proliferation and apoptosis of
human glioma cell lines (including the U87 and U251
cell lines) and the possible molecular mechanisms
underlying these actions, which indicate that Sch B may
be a new natural anti-tumour medicine for gliomas.
Results
Sch B inhibits the proliferation and viability of glioma
cells in a dose-dependent manner
We investigated the effect of Sch B on the proliferation
of various glioma cells using the MTT assay. U87 and
U251 cells were treated with various concentrations (0,
20, 40, 80 and 160 μmol/L for both cell lines) of Sch B
for 24, 48, and 72 h, then their viability was evaluated.
As shown in Figure 2A, Sch B induced a dose- and a
time-dependent reduction in the viability of U87 and
U251 cells. The IC50 values (the drug concentration that
inhibited 50% of the cells) of Sch B in U87 and U251
cells at 48 h were approximately 70 μmol/L and 60
μmol/L, respectively. We next tested the effect of Sch B
on the ability of U87 and U251 cells to form colonies.
Sch B induced a dose-dependent decrease in colony for-
mation in both glioma cell lines (Figure 2B). Moreover,
statistical analysis confirmed that the mean size of thecontrol colonies was larger than that of the Sch B-
treated group (Figure 2B). These data support the ability
of Sch B to significantly inhibit the proliferation of gli-
oma cells.
Sch B induces G0/G1 phase arrest by regulating the
expression of cell cycle-related proteins in U87 and
U251 cells
To further understand the mechanism underlying the
Sch B-mediated growth-inhibitory effect in human glioma
cells, we performed cell cycle analysis in U87 and U251
cells in the presence of Sch B. Sch B-mediated changes
in the cell cycle of U87 and U251 cells are shown in
Figure 3A and B. After treatment with Sch B for 48 h,
the percentage of G0/G1-phase cells dramatically in-
creased (from 63.2% to 82.5% for U87 cells, p < 0.01;
from 64.5% to 84.7% for U251 cells, p < 0.01), whereas
the percentage of cells in S-phase slightly decreased
compared with that of control cells.
Next, we assessed the levels of the G0/G1 phase-
related proteins cyclin D1 and cyclin-dependent kinase 4
(CDK4) using western blot analysis. As shown in Figure 3C,
Sch B treatment reduced the expression of cyclin D1 and
CDK4 in a dose-dependent manner, which is consistent
with G0/G1 phase arrest induced by Sch B.
Sch B induces apoptosis in human glioma cells
To further examine whether Sch B restrained the growth
of U87 and U251 cells through the induction of apop-
tosis, we performed annexin V/propidium iodide (PI)
double staining followed by flow cytometric analysis
after treating the cells with various doses of Sch B. One
of the distinct phenomenon of apoptosis is the trans-
location of phosphatidylserine (PS) from the inner leaflet
to the outer leaflet of the plasma membrane. As the hu-
man anticoagulant annexin-V has a high affinity for PS,
apoptotic cells can be identified via fluorophore-labelled
annexin-V. In addition, PI can detect necrotic cells due
to its ability to enter disrupted cell membranes. There-
fore, various cell populations can be easily distinguished
using annexin V/PI staining. As shown in Figure 3A,B,
The number of late apoptotic cells (from 4.2% to 65.6%
for U87 cells, p < 0.01; from 5.7% to 62.8% for U251 cells,
p < 0.01) was dramatically increased in a dose-dependent
manner after Sch B treatment compared with the control
group. Furthermore, morphological changes in the apop-
totic cells were investigated using Hoechst 33342 staining.
When U87 and U251 cells were exposed to different doses
of Sch B for 48 h, the number of apoptotic cells containing
condensed and fragmented nuclei increased significantly
as the dose of Sch B increased (Figure 4C,D). These re-
sults indicate that the apoptotic pathway plays a pivotal
role in the anti-proliferation effect of Sch B on U87 and
U251 cells.
Figure 2 (See legend on next page.)
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Figure 2 Sch B reduces the proliferation and viability of glioma cells. A. U87 and U251 cells were treated with various concentrations of Sch
B for 24, 48 and 72 h. Cell viability and IC50 values were measured using the MTT assay. B and C. U87 and U251 cells were treated with Sch B(4, 8,
16μmol/L ) for 48 h and were then allowed to form colonies in fresh medium for 14 days. Representative Giemsa staining pictures of the colonies
were shown (B). The numbers of colonies of U87 and U251 cells (C) were counted. The data shown are the mean ± SD of three independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.001 vs. the control group.
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(ΔΨm) in glioma cells
Mitochondria are key regulators of apoptosis, and apop-
tosis mediated by the mitochondrial pathway is often
associated with decreased ΔΨm. To examine whether
the mitochondrial membrane integrity is damaged by
Sch B treatment, rhodamine 123 was used to determine
ΔΨm in Sch-B treated glioma cells. Compared with the
control cells, Sch B treatment induced a dose-dependent
decrease in ΔΨm (Figure 5A,B). We found that more
than 80% of U87 cells and 76% of U251 cells showed a
reduction in ΔΨm after treatment with 100 μmol/L Sch
B for 48 h. These findings suggest that Sch B could re-
duce the mitochondrial membrane potential and induce
mitochondrial dysfunction in glioma cells, indicating
that Sch B promotes glioma cell apoptosis through a
mitochondrial-dependent apoptotic pathway.
Sch B-induced apoptosis via the regulation of caspase-3
and Bcl-2 family members in glioma cells
Many studies have shown that the Caspase family, Bcl-2
family and PARP play critical roles in apoptosis [16-18].
To investigate the potential molecular mechanisms re-
sponsible for Sch B-induced apoptosis of U87 and U251
cells, we detected the expression of apoptosis-related
proteins (Bax, Bcl-2, cleaved caspase-3 and cleaved
caspase-9) after treating the cells with various doses of
Sch B for 48 h. As shown in Figure 6A, Sch B treatment
leads to the upregulation of cleaved PARP, Bax, cleaved
caspase-9, and cleaved caspase-3 and the downregula-
tion of Bcl-2 in a dose-dependent manner. In addition,
the Bcl-2 (antiapoptotic) to Bax (proapoptotic) ratio was
significantly reduced compared with the control group
(Figure 6B). In summary, Sch B promotes apoptosis
through the regulation of apoptosis-related protein ex-
pression in glioma cells.
Sch B reduced tumour growth in vivo
To further investigate the effect of Sch B on tumour
growth in vivo, we intraperitoneally injected vehicle
(PBS) or Sch B (25 mg/kg, 100 mg/kg) into nude mice
carrying subcutaneous U87 tumour xenografts every 2
days for up to 20 days. As shown in Figure 7B, the tumor
weight was dramatically reduced after treatment with Sch
B(1.98 ± 0.07g in the 25 mg/kg group vs. 3.08 ± 0.15 in the
control group, p < 0.05; 1.08 ± 0.08g in the 100mg/kg
group vs. 3.08 ± 0.15 in the control group, p < 0.01). Ourresults showed that Sch B significantly inhibited tumour
growth in a dose-dependent manner compared with tu-
mours in the control group (Figure 7A,B,C).
Discussion
It has been reported that Sch B possesses anti-neoplastic
ability in a broad range of human cancers by promoting
apoptosis [10-12]. However, the effect of Sch B on glioma
cells and its underlying mechanisms remain largely un-
known. In the present study, we demonstrated that Sch B
inhibited proliferation, induced apoptosis and G0/G1
phase arrest in glioma cells and strongly restrained the
tumour growth in vivo. Thus, Sch B may be a promising
drug to treat gliomas.
Results of cell cycle distribution experiment in the
presence of Sch B demonstrated that it induced G0/G1
phase arrest after 48 h of treatment and that prompted
us to further investigate the mechanism of cell cycle
arrest. Cyclins and CDKs play key roles in cell cycle
regulation [19]. Cyclin D1, one of the key cell cycle regula-
tory molecules [20,21], can form a complex with CDK4 to
promote the transition of cells from G0/G1 to S phase by
catalysing the phosphorylation of retinoblastoma (Rb)
[22-24]. Indeed, we observed that Sch B downregulated
the expression of cyclin D1 and CDK4 in both U87 and
U251 cells (Figure 3C). Based on these data, we believe
that Sch B arrests the cell cycle in G0/G1-phase to sup-
press the proliferation of glioma cells by reducing the ex-
pression of cyclin D1 and CDK4.
The deregulation of apoptosis has frequently been ob-
served in various cancers; thus, the induction of apoptosis
has been proposed as an important strategy to treat cancer
[25,26]. Generally, there are two major pathways that con-
trol the initiation of apoptosis: the death-receptor-induced
extrinsic pathway and the mitochondria-apoptosome-
mediated intrinsic pathway, both of which ultimately
activate a series of effector caspases and apoptosis effector
molecules [27]. In the extrinsic pathway, the binding of li-
gands to membrane death-receptors leads to the activa-
tion of caspase-8; In the intrinsic pathway, Bax induces
the release of cytochrome c from the mitochondria, lead-
ing to the apoptosome formation and activation of caspase
9, and subsequent caspase 3 activation. Caspase-3 is one
of the most important executioner caspases and is capable
of cleaving many important cellular substrates, such as
PARP, resulting in apoptosis progression, morphological
changes, and DNA fragmentation [28]. In our study, Sch
Figure 3 Effect of Sch B on cell cycle progression in glioma cells. A. U87 and U251 cells were exposed to various concentrations of Sch B (0,
25, 50, 100 μmol/L) for 48 h and then analysed using flow cytometry. B. The percentages of the total cell population in the G0/G1, S, and G2/M
phases of the cell cycle are calculated. C. Effects of Sch B on the protein levels of cyclin D1 and CDK4 in U87 and U251 cells were measured by
western blot analysis, with β-actin as a loading control.
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Figure 4 Sch B induces apoptosis in U87 and U251 cells. U87 and U251 cells were exposed to various concentrations of Sch B for 48 h.
A. Sch B treated cells were stained with annexin-V/propidium iodide (PI). The Q3 (annexin-V−/PI−), Q4 (annexin-V+/PI−) and Q2 (annexin-V+/PI+)
quadrants represent the populations of normal, early apoptotic and late apoptotic cells, respectively. B. Percentages of surviving cells and early
and late apoptotic cells are shown as the means ± SD (n = 3). C. Apoptotic nuclear morphological changes induced by Sch B (0, 25, 50, 100 μmol/L) for
48 h were observed using Hoechst 33342 staining in U87 and U251 cells. The arrowheads indicate apoptotic cells, which exhibited highly condensed
and fragmented nuclear morphologies. D. Percentages of apoptotic cells are shown as the means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001
compared with the control group.
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and caspase-3, accompanied by increased PARP cleavage,
suggesting that the mitochondrial pathway was involved
in Sch B-induced apoptosis. Proteins in the Bcl-2 family,
including the apoptosis-promoting protein Bax and anti-
apoptotic protein Bcl-2, are the key regulators of the
mitochondria-mediated apoptosis pathway [29,30]. It has
been reported that a low Bcl-2 to Bax ratio can cause
ΔΨm collapse, the release of cytochrome c, and subse-
quent apoptosis [31]. In the present study, we found
that the ratio of Bcl-2 to Bax was reduced by 15.6- and
10.24-fold after treatment with 100 μmol/L Sch B in
U87 and U251 cells, respectively, compared with that
of the control group. As a result, a significant decrease
of ΔΨm was observed in giloma cells.
To further address the antitumor activity of Sch B
against glioma, the animal work should be taken entirely.
Due to the prolonged tissue culture, the genetic and mor-
phologic characteristics of established cell lines often differ
from the primary human tumors. To overcome these
shortcomings, Sarkaria lab [32] have developed a model of
primary glioblastoma multiforme (GBM) xenografts that
were established by engraftment of patient tumor speci-
mens directly into the flank of nude mice. These xenograft
lines remains key genetic features of the corresponding
patient tumor, this is highly useful for both basic and
translational studies. We can use this model to test the
effect of Sch B on patient tumor specimens. The exten-
sion of animal numbers is also needed to further con-
firm the clinical significance of Sch B on the treatment
of glioma.
Conclusion
In summary, our study suggests that Sch B attenuates
the proliferation of U87 and U251 cells and arrests cell
cycle in the G0/G1 phase. Sch B induces cell apoptosis
by increasing Bax, cleaved caspase-9, cleaved caspase-3,
and cleaved PARP and reducing Bcl-2 protein expression
in glioma cells. Furthermore, Sch B dramatically inhib-
ited tumour growth in vivo. All of the above results in-
dicate that Sch B may be a promising drug for glioma
treatment. However, further studies are needed to
understand the fundamental mechanism underlying
the apoptosis and cell cycle arrest induced by Sch B in
glioma cells.Methods
Drugs and antibodies
Sch B was purchased from Sigma-Aldrich (St. Louis,
MO, USA) and dissolved in dimethyl sulfoxide (DMSO,
Sigma-Aldrich) to obtain a 100 mM stock solution, which
was then diluted in the culture medium to yield the de-
sired Sch B concentration. An equal volume of DMSO in
complete culture medium was used as the vehicle control.
To eliminate the cytotoxicity of DMSO, the final concen-
tration of DMSO for all experiments was maintained at
less than 0.1%. Rhodamine 123 and 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT)
were purchased from Sigma Chemical Co. Primary anti-
bodies against Bcl-2, Bax, cleaved caspase-9, cleaved
PARP, cleaved caspase-3, cdc-2, cyclin D1, and GAPDH
and secondary antibodies (goat anti-rabbit) were all
purchased from Cell Signaling Technology (Danvers,
MA, USA).Cell lines and culture
The human glioma U87 and U251 cell lines were pur-
chased from the Shanghai Institute of Cell Biology,
Chinese Academy of Sciences (CAS, Shanghai, China).
All cells were cultured in high-glucose DMEM (Gibco,
Grand Island, NY, USA) supplemented with 10% foetal
bovine serum (Gibco), 100 μg/mL streptomycin, and
100 U/mL penicillin (HyClone, USA).The cells were
cultured in an atmosphere containing 5% CO2 at 37°C.Cell viability assay
The viability of cells treated with Sch B was measured
as previously described [33]. Briefly, cells were seeded
into 96-well culture plates at 5,000 cells/well, incu-
bated overnight, then treated with 0, 20, 40, 60, 80
and 160 μmol/L Sch B for 24, 48 and 72 h. Next,
added 20 μL MTT solution (5 mg/mL) to each well
for another 4 h after treatment. In order to solubilise
the formazan crystals, 100 μL DMSO was added to
each well. The absorbance was determined at 490 nm
using a microplate reader (Bio-Tek, Winooski, VT,
USA). The cell survival rate was measured as the ab-
sorbance compared with that of untreated controls.
The results represent the average of 3 independent
experiments.
Figure 5 Sch B decreases the mitochondrial membrane potential (ΔΨm) in glioma cells. U87 and U251 cells were treated with Sch B (0, 25,
50, 100 μmol/L) for 48 h. A. Flow cytometric analysis of ΔΨm by rhodamine 123 staining. B. The corresponding histogram shows the percentages
of cells with high ΔΨm (survival) and low ΔΨm (apoptosis). Values represent the means ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001 compared
with the control group.
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Briefly, cells in the logarithmic growth phase were
seeded into 6-well plates (Corning, Corning, NY, USA)
at a density of 400 cells/well and allowed to grow for 24 h.
The cells were then treated with Sch B (0, 4, 8 and 16
μmol/L) for another 48 h. The Sch B-containing medium
was then discarded, and the cells were washed with PBSand cultured to form colonies in complete medium for an-
other 14 days. Next, the cells were fixed with 4% parafor-
maldehyde for 15 min at room temperature and stained
with 0.1% crystal violet (Sigma-Aldrich) for 30 min. After
washing, the total number of colonies (>50 cells/colony)
was counted manually and the stained colonies were photo-
graphed using a microscope (Leica, Wetzlar, Germany).
Figure 6 Sch B induces apoptosis via the regulation of apoptosis-related proteins in glioma cells. A. After treatment with Sch B (0, 25, 50,
100 μmol/L) for 48 h, cell lysates of U87 and U251 cells were prepared, and the expression of cleaved caspase-3, cleaved PARP, Bax and Bcl-2 were
analysed using western blot. β-actin was used as a loading control. B. The ratio of Bcl-2 to Bax was calculated by band density. The results were
shown as the mean ± SD compared with the control (designated as 1.00). *P < 0.05; **P < 0.01 compared with the control group.
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pendent experiments.
Cell cycle analysis
U87 and U251 cells were treated with various concentra-
tions of Sch B for 48 h. Both adherent and floating cells
were harvested, washed twice in cold PBS, and fixed in
70% ethanol at 4°C overnight. After fixation, the cells
were washed and incubated in staining buffer (10 mg/mL
RNase and 1 mg/mL propidium iodide (Sigma-Aldrich))
at 37°C in the dark for 30 min. Subsequently, the samples
were analysed using flow cytometry (BD Biosciences, San
Diego, CA, USA). The percentages of cells in the G0/G1,
S, and G2/M phases were calculated using Cell Quest
acquisition software (BD Biosciences).
Cell apoptosis assay
Apoptosis was analysed using the annexin V/PI apoptosis
kit according to the manufacturer’s recommendations (BDBiosciences, San Diego, CA, USA). Briefly, Two hundred
thousand cells (2 × 105) were first seeded into 6-well plates
and treated with Sch B (0, 25, 50, and 100 μmol/L) for 48
h. The cells were then harvested and resuspended at a
density of 1 × 106 cells/mL in binding buffer. Then 5 μL
annexin V-FITC and 5 μL PI (100 μg/mL) were added to
the suspension cells. After incubation for 15 min in the
dark at room temperature, 400 μL of the binding buffer
was added to the cell suspension. The stained cells were
then immediately analysed using flow cytometry (BD Bio-
sciences, San Diego, CA, USA). Each sample was assayed
in duplicate, and the experiment was repeated three times.
Hoechst 33342 staining assay
Nuclear fragmentation was determined by staining apop-
totic nuclei with Hoechst 33342. U87 and U251 cells were
treated with various concentrations of Sch B for 48 h, the
cells were harvested, washed in cold PBS and fixed with
acetic acid:ethanol (1:3) for 15 min at room temperature.
Figure 7 Sch B inhibited the growth of U87 cells in vivo. A. U87 cells were subcutaneously injected into the left flank of nude mice. Then, 0.1
mL vehicle (PBS) or Sch B (25 and 100 mg/kg) was intraperitoneally administered to the animals every 2 days for up to 20 days. Photos of one
representative mouse (n = 6) from each group are shown. B. Tumours were excised and weighed in each group. *P < 0.05, **P < 0.01; ***P < 0.001
vs. the control group. C. Tumor dimensions were periodically measured using callipers.
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Hoechst 33342 for 10 min. Digital images were captured
under a fluorescence microscope (Leica, Germany).
Mitochondrial membrane potential (ΔΨm) assay
Rhodamine 123 (Rho123) was used to determine the
mitochondrial membrane potential (ΔΨm) as previously
described [34]. Briefly, after treatment with various con-
centrations of Sch B for 48 h, U87 and U251 cells were
collected and washed twice with cold PBS. The cells
were then stained with Rhodamine 123 (Sigma-Aldrich)
for 30 min at 5% CO2 and 37°C in the dark. The samples
were then analysed using flow cytometry (BD Biosciences,
San Diego, CA, USA). Each assay was carried out in tripli-
cate, and the results were expressed as the mean ± SD.
Western blot analysis
U87 and U251 cells were treated with Sch B (0, 25, 50
and 100 μmol/L) for 48 h, total protein was extracted
using RIPA buffer (Beyotime Institute of Biotechnology,
Beijing, China) supplemented with protease inhibitor
(Roche Applied Science, Indianapolis, IN, USA) at 4°C
for 5 min. The protein concentration was determined
using the bicinchoninic acid (BCA) assay kit (Beyotime).
Total protein samples (40 μg/lane) were separated using
10% SDS-PAGE and then electrophoretically transferredto polyvinylidene difluoride membranes (Millipore,
Bedford, MA, USA). After blocking with 5% skim milk
for 1–2 h at room temperature, the membranes were then
incubated with the indicated primary antibodies against
Bcl-2, Bax, cleaved PARP, cleaved caspase-9, cleaved
caspase-3, CDK4, cyclin D1, and β-actin (1:1000) at 4°C
overnight. The membranes were then washed with TBST
buffer for 3 × 5 minutes and incubated with the secondary
antibodies (HRP-conjugated goat anti-rabbit IgG) for 1 h
at room temperature. The bands were detected using en-
hanced chemiluminescence and visualised by a Gel Doc
2000 (BioRad, Hercules, CA, USA).
In vivo tumour xenograft study
BALB/c homozygous (nu/nu) nude mice (6–8 weeks
old, 18–20 g body weight) that had been bred in house
were maintained in a specific pathogen-free environ-
ment. U87 cells in log-phase growth (2.5 × 106) were
suspended in 100 μL PBS and then subcutaneously
injected into the left flank of the nude mice. Twenty-
four hours post inoculation, the mice were randomly
divided into three groups (6 mice/group). The control
group was administered PBS intraperitoneally and the
other two treatment groups were administered Sch B
(25 and 100 mg/kg) intraperitoneally in a volume of 0.2
mL every 2 days for up to 20 days. On day 22, all mice
Li et al. Cancer Cell International  (2015) 15:12 Page 11 of 11were sacrificed, and the tumours were excised and
weighed. The experimental procedure was conducted
according to the institutional animal care guideline
and approved by the Laboratory Animal Ethics Com-
mittee of Wenzhou Medical University with the refer-
ence number wydw2014-0026.
Statistical analysis
All data were expressed as the mean ± SD of at least three
independent experiments. Differences between groups
were analyzed using the Student’s t test,. A P-value of
less than 0.05 (denoted by *) was considered to be sta-
tistically significant.
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